






1



2



3




4




5




6



7



8




9

PEER REVIEW

Rejections before review (Most are referred to the Transfer Desk)

Category	Manuscript Title
Case Report	Durable Complete Response in HER2-Positive Metastatic Gastroesophageal Junction Adenocarcinoma with Later-Line EOX Chemotherapy and Radiotherapy for Oligoprogression: A Case Report
Large Database	Acute Myeloid Leukemia and Myelodysplastic Following PARP Inhibitors: A Pharmacovigilance Analysis From A Large National Database
Non-oncology	Efficacy of local minocycline ointment after periodontitis implant surgery and its effect on inflammatory factors and postoperative infection
Non-oncology	FORMULATION OF SITAGLIPTIN NANOSUSPENSION AND EVALUATION OF ITS IN VITRO NEUROPROTECTIVE ACTIVITY AGAINST ALZHEIMER'S DISEASE PATHWAYS
Non-oncology	Therapeutic effects of acupuncture combined with betahistine mesylate on Meniere's disease and their impact on vertigo and pure-tone hearing thresholds
Non-oncology	Efficacy and safety of combined medicated cupping therapy and Kegel exercises for fecal incontinence in ulcerative colitis: impact on inflammation, intestinal barrier, and quality of life
Non-oncology	Effects of sacubitril/valsartan combined with ShensongYangxin Capsules on cardiac function and NT-proBNP levels in patients with persistent atrial fibrillation
Non-oncology	Comparing hyaluronate drops to combined IPL and Chinese medicine in perimenopausal women
Non-pharmacy	Application of the PDCA cycle combined with blended teaching in endocrinology internship training: effects on clinical competence and learning engagement
Non-pharmacy	Application of disease- and symptom-integrated teaching in perioperative nursing education for prostate cancer
Precinical	Expression and clinical significance of MC-LR, TFF3, and CHS1L1 in patients with primary liver cancer

10



11

PRODUCTION

Output & Publishing Pace

Year	Volume	Issues	Pages Published	Articles Published
2024	30	10	1,451	200
2025	31	10	1,518	221
2026 YTD	32	6	786	140

1,518
Pages published in 2025 across 10 issues


221
Articles published in 2025 (28 of them Open Access)

22 days
Median accept-to-online publication time


10 issues and 1,518 pages were published in 2025, with 786 pages already out in 2026 year-to-date. The page budget remains flexible across regular issues and supplements.

Journal of Oncology/Pharmacy Practice - Publisher's Report

12



13



14

HOW THE BOARD CAN HELP

Actions for Editorial Board & Society Members

01 Solicit submissions Recruit standout posters, presentations, and colleagues' work at conferences and lectures.	02 Recruit reviewers Bring new contacts into the pool — authors of noteworthy papers and early-career researchers.	03 Recommend special issues Flag hot topics and emerging trends to build highly cited collections.
04 Mentor junior scholars Engage early-career researchers through co-authorship and quality review training.	05 Share & promote Reference your role on social media, share read-only articles, and link work to the journal.	06 Champion subscriptions Encourage your library or institution to subscribe and recommend the journal.

Thank you for your partnership in advancing oncology pharmacy practice.

15

Automatic Plagiarism Check [CrossRef (iThenticate)]

- iThenticate is a plagiarism checking software
- Cross-references a manuscript with published content from:
 - 93% of top cited journals
 - > 70 billion current and archived web pages
- Generates originality or similarity report
- Overall percentage match with previously published work
 - Highlights potential individual matches
 - Overlap with other work

16

Automatic Plagiarism Check [CrossRef (iThenticate)]

- Enables early detection of text similarity, helping to prevent ethical concerns post acceptance
- Supports informed editorial decision-making with transparent and reliable data
- Enhance efficiency by identifying potential issues before peer review
- Reduces the likelihood of post-publication corrections or retractions
- Strengthens the journal's commitment to research integrity and publication ethics

17

Automatic Plagiarism Check [CrossRef (iThenticate)]

Plagiarism Check iThenticate User Guide


Crossref
Similarity Check
Powered by iThenticate

Overall Similarity Index Percentage: 34%
Report complete. [View the Originality Report.](#)

top

18

Automatic Plagiarism Check [CrossRef (iThenticate)]



19

Automatic Plagiarism Check [CrossRef (iThenticate)]

Multivariate logistic regression analysis, with the presence of PLC as the dependent variable and MC-LR, TF3, and CHIL1 as independent variables, identified TF3 and CHIL1 as independent risk factors for PLC ($P < 0.05$) (Table 4). ROC curve analysis also demonstrated that the areas under the curve (AUCs) for MC-LR, TF3, and CHIL1 were 0.652 (95% CI: 0.573-0.728), 0.850 (95% CI: 0.793-0.907), and 0.966 (95% CI: 0.937-0.995), respectively. The combined diagnostic model incorporating all three biomarkers yielded an AUC of 0.983, which was superior to the diagnostic performance of each individual marker (Table 5, Figure 1).

Bioinformatics analysis of TF3 and CHIL1 expression and patient survival

Bioinformatics analysis using the GEPIA database demonstrated that both TF3 and CHIL1

public-papers-files-2025-frontiersin-org/journal-article/article/10.3389/fendo.2025.1491224/pdf#CF

GGT $p = 0.135$, $p = 0.027$, $Crp = 0.123$, $p = 0.049$, $Tbip = 0.176$, $p = 0.013$, $Tch = 0.136$, $p = 0.049$, $Lpa = 0.172$, $p = 0.015$, $Wbc = 0.415$, $p = 0.011$, $Hbc = 0.166$, $p = 0.007$, $Hb = 0.122$, $p = 0.048$, and $Pct = 0.501$, $p = 0.001$. Conversely, it was negatively correlated with $Fo-4$ ($p = 0.309$, $p < 0.005$) and $Cd4$ ($p = 0.225$, $p = 0.006$) (Figure 2). In the overall cohort ($n = 348$), serum apolipoprotein was positively correlated with $Tbip$ ($p = 0.111$, $p = 0.037$), Alb ($p = 0.136$, $p = 0.013$), Tch ($p = 0.149$, $p = 0.00$).

View Full Text

Frontiers Media Limited

20

Automatic Plagiarism Check Immediate Rejection Emails

- **Unsubmit for Duplication**
 - During internal checks, it has come to our attention that a significant proportion of your paper has been presented in one of your prior publications.
 - **Unsubmit for Plagiarism**
 - During internal checks, it has come to our attention that a significant proportion of your paper overlaps with previously published material.
-
- You may know that text re-use without proper attribution to the original source is a breach of publication ethics principles. Sage takes issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously and investigates all allegations in adherence to COPE guidelines.
- Therefore, we are unable to consider your paper (Document not available) at this time as it contains material which has been previously published. However, the journal would welcome a resubmission if you are able to reference the original material correctly and/or remove the duplicated/overlapping material.

21

AI in Publishing

- **Sage AI Policy**
 - <https://www.sagepub.com/journals/publication-ethics-policies/artificial-intelligence-policy>
 - Sage recognizes that large language models (LLMs) or Gen AI offer opportunities for acceleration in research and its dissemination. While these opportunities can be transformative, they are unable to replicate human creative and critical thinking. We distinguish various uses for AI and related technologies as: assistive (and no longer requiring disclosure), generative (requiring disclosure), and prohibitive. Sage's policy on the use of AI technology has been developed to assist authors, reviewers and editors to make good judgements about the ethical use of such technology.
- **AI assistance (no disclosure required)**
- **AI generated (disclosure required)**
- **Prohibited use of AI**
- **Undisclosed use of AI/LLM tools**

22

Appropriate Uses for Generative AI

- **AI generated (disclosure required)**
 - **Authors must take steps to verify the accuracy of all outputs and check the original sources.**
- Assistance with literature review or compilation of relevant sources
- Translation of materials as part of the research process
- Using software or code generated by AI to undertake additional research
- Assistance in research data visualization
- Generation of representative illustrations or infographics
- Code enhanced or checked for errors by AI assistance
- Assistance with compilation of references


23

Fabricated References



24

Fabricated References



Lancet 2026;407: 1779-1781

25

How can reviewers assist with AI detection?



AI Detection for Peer Reviewers: Look out for Red Flags

- **Sage Resource** (https://www.sagepub.com/explore-our-content/blogs/posts/sage-perspectives/2025/06/11/ai-detection-for-peer-reviewers-look-out-for-red-flags?utm_source=selligent&utm_medium=email&utm_campaign=sage_awa_away_oth_q2-editor-newsletter&utm_content=26u2670724_a&utm_term=&m_i=nPTEDxP7iv67IF%2Bxm5OdQJ2mVoxPZ%2BEQe%2BCwVCCqHx8LBfRz3Wwz7GjppCacNSK2wjxqRvfoktkBBNavXOY6imZQX_wRunnnf&nbd=10017951&nbd_source=signt&M_BT=50181218904826)
- **Sage's Artificial Intelligence Policy** (<https://www.sagepub.com/journals/editorial-policies/artificial-intelligence-policy>)
- **Aspirative and generative AI guidelines for authors** (<https://www.sagepub.com/about/policies/ai-author-guidelines>)
- Writing Style
- Citations
- Content/Logic
- Visual or Data
- Unusual formatting or Visual

Lancet 2026;407: 1779-1781

26

What can Editors do?

- **Verify References:** Check the legitimacy of all citations.
- **Request Raw Data or Methodological Clarification:** Ask for additional details to ensure the research is sound.
- **Recommend Careful Revision:** Suggest further clarification from authors.
- **Ask for a Cover Letter:** Request a detailed cover letter outlining the research process.

Lancet 2026;407: 1779-1781

27

THE DECISION

*To always disclose
or option to disclose
(when not required)*

Production staff does not remove anything from submission

28

Open Discussion



29